



Lotemax[®] (loteprednol etabonate) – First-time generic

- On May 6, 2019, Akorn launched an **AB-rated** generic version of Bausch Health's **Lotemax (loteprednol etabonate)** 0.5% ophthalmic suspension.
- Lotemax is indicated for the treatment of post-operative inflammation and pain following ocular surgery.
- Loteprednol etabonate is also available as brand 0.2% ophthalmic suspension (**Alrex[®]**), 1% ophthalmic suspension (**Inveltys[™]**), 0.5% ophthalmic gel (**Lotemax**), 0.5% ophthalmic ointment (**Lotemax**), 0.38% ophthalmic gel (**Lotemax SM**), and 0.5% ophthalmic suspension in combination with tobramycin (**Zylet[®]**).
 - Alrex is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
 - Inveltys, Lotemax gel, Lotemax ointment and Lotemax SM carry the same indication as Lotemax ophthalmic suspension.
 - Zylet is approved for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
- According to IQVIA, U.S. sales of Lotemax 0.5% were approximately \$89 million for the twelve months ending in February 2019.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.